Sensory Organ Drugs - Sudan

Sudan

The Sensory Organ Drugs market in Sudan is expected to witness significant growth in the coming years.
By 2024, the revenue in this market is projected to reach US$1.35m.
Furthermore, it is anticipated that there will be a steady annual growth rate (CAGR 2024-2029) of -5.08%, leading to a market volume of US$1.04m by 2029.
When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue, amounting to US$13,980.00m in 2024.
Sudan's market for sensory organ drugs is experiencing a surge in demand due to the country's high prevalence of eye-related diseases.

Key regions: Australia, France, Brazil, Italy, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Sensory Organ Drugs market in Sudan has been experiencing steady growth in recent years.

Customer preferences: Sudan has a large population with a high incidence of sensory organ diseases such as cataracts and glaucoma. As a result, there is a high demand for sensory organ drugs in the country. Customers in Sudan often prefer affordable drugs that are effective in treating their conditions.

Trends in the market: There has been an increase in the number of pharmaceutical companies operating in Sudan, leading to greater competition in the market. This has resulted in lower prices for sensory organ drugs, making them more accessible to a wider population. Additionally, there has been a rise in the availability of generic drugs, which are often cheaper than branded alternatives.

Local special circumstances: Sudan has a relatively underdeveloped healthcare system, with limited access to medical facilities, particularly in rural areas. This has led to a greater reliance on pharmaceutical drugs to treat illnesses. Furthermore, there is a lack of regulation in the pharmaceutical industry, which has led to concerns about the quality of drugs available in the market.

Underlying macroeconomic factors: Sudan is a low-income country with a GDP per capita of less than $2,000. This has led to a high level of poverty, which has in turn affected the affordability of healthcare. Additionally, Sudan has experienced political instability and conflict in recent years, which has had a negative impact on the economy. Despite these challenges, the government has made efforts to improve access to healthcare, which has contributed to the growth of the Sensory Organ Drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.